Teriflunomid zur Behandlung der Multiplen Sklerose

Translated title of the contribution: Teriflunomide for treatment of multiple sclerosis

C. Warnke, G. Meyer Zu Hörste, T. Menge, O. Stüve, H. P. Hartung, H. Wiendl, B. C. Kieseier

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Summary: Interferon beta and glatiramer acetate are still considered to be the first-line therapeutics for treatment of relapsing forms of multiple sclerosis (MS). The use of new compounds, such as natalizumab or fingolimod, is restricted to severe forms of relapsing MS or cases refractory to first-line treatment owing to substance-specific risk-benefit considerations. Teriflunomide is a new compound which has recently been approved as a first-line treatment of relapsing forms of MS in the USA and Australia. It is characterized by a once daily oral administration and a comparably well-established long-term safety profile. The main therapeutic effect is considered to be mediated via the inhibition of the de novo synthesis of pyrimidine in proliferating immune cells. The pro-drug of teriflunomide, leflunomide, has a label for treating rheumatoid arthritis (RA) for many years. Two recently published phase III clinical trials (TEMSO, TOWER) tested teriflunomide in patients with relapsing forms of MS and efficacy was demonstrated, with positive effects on relapse rates and disease progression using 14 mg/day. Overall, the safety profile in these studies was favorable as expected from experiences with leflunomide in RA. In patients treated with teriflunomide regular monitoring of blood cell counts and liver enzymes is required. Teriflunomide must not be used during pregnancy. In this article the recent phase II and phase III clinical trial data are reviewed and the potential of teriflunomide for the treatment of relapsing forms of MS is discussed.

Original languageGerman
Pages (from-to)724-731
Number of pages8
JournalNervenarzt
Volume84
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Multiple Sclerosis
leflunomide
Phase III Clinical Trials
Rheumatoid Arthritis
Therapeutics
Safety
Blood Cell Count
Interferon-beta
Prodrugs
Therapeutic Uses
Oral Administration
Disease Progression
teriflunomide
Recurrence
Pregnancy
Liver
Enzymes

Keywords

  • First-line therapeutics
  • Immunotherapy
  • Leflunomide
  • Multiple sclerosis
  • Oral therapy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Psychiatry and Mental health

Cite this

Warnke, C., Meyer Zu Hörste, G., Menge, T., Stüve, O., Hartung, H. P., Wiendl, H., & Kieseier, B. C. (2013). Teriflunomid zur Behandlung der Multiplen Sklerose. Nervenarzt, 84(6), 724-731. https://doi.org/10.1007/s00115-013-3779-7

Teriflunomid zur Behandlung der Multiplen Sklerose. / Warnke, C.; Meyer Zu Hörste, G.; Menge, T.; Stüve, O.; Hartung, H. P.; Wiendl, H.; Kieseier, B. C.

In: Nervenarzt, Vol. 84, No. 6, 06.2013, p. 724-731.

Research output: Contribution to journalArticle

Warnke, C, Meyer Zu Hörste, G, Menge, T, Stüve, O, Hartung, HP, Wiendl, H & Kieseier, BC 2013, 'Teriflunomid zur Behandlung der Multiplen Sklerose', Nervenarzt, vol. 84, no. 6, pp. 724-731. https://doi.org/10.1007/s00115-013-3779-7
Warnke C, Meyer Zu Hörste G, Menge T, Stüve O, Hartung HP, Wiendl H et al. Teriflunomid zur Behandlung der Multiplen Sklerose. Nervenarzt. 2013 Jun;84(6):724-731. https://doi.org/10.1007/s00115-013-3779-7
Warnke, C. ; Meyer Zu Hörste, G. ; Menge, T. ; Stüve, O. ; Hartung, H. P. ; Wiendl, H. ; Kieseier, B. C. / Teriflunomid zur Behandlung der Multiplen Sklerose. In: Nervenarzt. 2013 ; Vol. 84, No. 6. pp. 724-731.
@article{3c1e968082fe4611b91bfbc0eac599d9,
title = "Teriflunomid zur Behandlung der Multiplen Sklerose",
abstract = "Summary: Interferon beta and glatiramer acetate are still considered to be the first-line therapeutics for treatment of relapsing forms of multiple sclerosis (MS). The use of new compounds, such as natalizumab or fingolimod, is restricted to severe forms of relapsing MS or cases refractory to first-line treatment owing to substance-specific risk-benefit considerations. Teriflunomide is a new compound which has recently been approved as a first-line treatment of relapsing forms of MS in the USA and Australia. It is characterized by a once daily oral administration and a comparably well-established long-term safety profile. The main therapeutic effect is considered to be mediated via the inhibition of the de novo synthesis of pyrimidine in proliferating immune cells. The pro-drug of teriflunomide, leflunomide, has a label for treating rheumatoid arthritis (RA) for many years. Two recently published phase III clinical trials (TEMSO, TOWER) tested teriflunomide in patients with relapsing forms of MS and efficacy was demonstrated, with positive effects on relapse rates and disease progression using 14 mg/day. Overall, the safety profile in these studies was favorable as expected from experiences with leflunomide in RA. In patients treated with teriflunomide regular monitoring of blood cell counts and liver enzymes is required. Teriflunomide must not be used during pregnancy. In this article the recent phase II and phase III clinical trial data are reviewed and the potential of teriflunomide for the treatment of relapsing forms of MS is discussed.",
keywords = "First-line therapeutics, Immunotherapy, Leflunomide, Multiple sclerosis, Oral therapy",
author = "C. Warnke and {Meyer Zu H{\"o}rste}, G. and T. Menge and O. St{\"u}ve and Hartung, {H. P.} and H. Wiendl and Kieseier, {B. C.}",
year = "2013",
month = "6",
doi = "10.1007/s00115-013-3779-7",
language = "German",
volume = "84",
pages = "724--731",
journal = "Der Nervenarzt",
issn = "0028-2804",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Teriflunomid zur Behandlung der Multiplen Sklerose

AU - Warnke, C.

AU - Meyer Zu Hörste, G.

AU - Menge, T.

AU - Stüve, O.

AU - Hartung, H. P.

AU - Wiendl, H.

AU - Kieseier, B. C.

PY - 2013/6

Y1 - 2013/6

N2 - Summary: Interferon beta and glatiramer acetate are still considered to be the first-line therapeutics for treatment of relapsing forms of multiple sclerosis (MS). The use of new compounds, such as natalizumab or fingolimod, is restricted to severe forms of relapsing MS or cases refractory to first-line treatment owing to substance-specific risk-benefit considerations. Teriflunomide is a new compound which has recently been approved as a first-line treatment of relapsing forms of MS in the USA and Australia. It is characterized by a once daily oral administration and a comparably well-established long-term safety profile. The main therapeutic effect is considered to be mediated via the inhibition of the de novo synthesis of pyrimidine in proliferating immune cells. The pro-drug of teriflunomide, leflunomide, has a label for treating rheumatoid arthritis (RA) for many years. Two recently published phase III clinical trials (TEMSO, TOWER) tested teriflunomide in patients with relapsing forms of MS and efficacy was demonstrated, with positive effects on relapse rates and disease progression using 14 mg/day. Overall, the safety profile in these studies was favorable as expected from experiences with leflunomide in RA. In patients treated with teriflunomide regular monitoring of blood cell counts and liver enzymes is required. Teriflunomide must not be used during pregnancy. In this article the recent phase II and phase III clinical trial data are reviewed and the potential of teriflunomide for the treatment of relapsing forms of MS is discussed.

AB - Summary: Interferon beta and glatiramer acetate are still considered to be the first-line therapeutics for treatment of relapsing forms of multiple sclerosis (MS). The use of new compounds, such as natalizumab or fingolimod, is restricted to severe forms of relapsing MS or cases refractory to first-line treatment owing to substance-specific risk-benefit considerations. Teriflunomide is a new compound which has recently been approved as a first-line treatment of relapsing forms of MS in the USA and Australia. It is characterized by a once daily oral administration and a comparably well-established long-term safety profile. The main therapeutic effect is considered to be mediated via the inhibition of the de novo synthesis of pyrimidine in proliferating immune cells. The pro-drug of teriflunomide, leflunomide, has a label for treating rheumatoid arthritis (RA) for many years. Two recently published phase III clinical trials (TEMSO, TOWER) tested teriflunomide in patients with relapsing forms of MS and efficacy was demonstrated, with positive effects on relapse rates and disease progression using 14 mg/day. Overall, the safety profile in these studies was favorable as expected from experiences with leflunomide in RA. In patients treated with teriflunomide regular monitoring of blood cell counts and liver enzymes is required. Teriflunomide must not be used during pregnancy. In this article the recent phase II and phase III clinical trial data are reviewed and the potential of teriflunomide for the treatment of relapsing forms of MS is discussed.

KW - First-line therapeutics

KW - Immunotherapy

KW - Leflunomide

KW - Multiple sclerosis

KW - Oral therapy

UR - http://www.scopus.com/inward/record.url?scp=84879506535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879506535&partnerID=8YFLogxK

U2 - 10.1007/s00115-013-3779-7

DO - 10.1007/s00115-013-3779-7

M3 - Article

C2 - 23695001

AN - SCOPUS:84879506535

VL - 84

SP - 724

EP - 731

JO - Der Nervenarzt

JF - Der Nervenarzt

SN - 0028-2804

IS - 6

ER -